Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4777474 | 1.00 | SIGMAR1 (0.54) | SIGMAR1POLBHSD17B10HTTL3MBTL3 | |
| SCHEMBL3272638 | 0.98 | SIGMAR1 (0.51) | SIGMAR1POLBHSD17B10HTTL3MBTL3 | |
| SCHEMBL15190856 | 0.98 | SIGMAR1 (0.51) | SIGMAR1POLBHSD17B10HTTL3MBTL3 | |
| SCHEMBL3272642 | 0.98 | SIGMAR1 (0.51) | SIGMAR1POLBHSD17B10HTTL3MBTL3 | |
| Oxalic Acid SCHEMBL4158692 | 0.94 | SIGMAR1 (0.49) | SIGMAR1POLBHSD17B10HTTL3MBTL3 | |
| SCHEMBL22191535 | 0.94 | SIGMAR1 (0.48) | SIGMAR1POLBHSD17B10HTTL3MBTL3 | |
| SCHEMBL22208127 | 0.86 | POLB (0.46) | SIGMAR1POLBHSD17B10HTTMEN1 | |
| SCHEMBL23573288 | 0.82 | POLB (0.56) | SIGMAR1POLBHSD17B10HTTMEN1 | |
| SCHEMBL3369574 | 0.82 | POLB (0.51) | SIGMAR1POLBHSD17B10MEN1KMT2A | |
| SCHEMBL854180 | 0.81 | PDE7A (0.46) | SIGMAR1POLBHSD17B10L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519124-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| EP-1961744-B1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-20120207765-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-16 | — | — | US | disclosed |
| EP-1961744-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120207765-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | CXCR4, CXCR3, CXCR1 | SIGMAR1 791/4885POLB 3903/4885HSD17B10 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.